Interested in Connecting? Please contact:
Daniel Figeys
Co-Founder and President

Message the company or request a 1:1 meeting here

Spin-off from the University of Ottawa that has a unique living microbiome platform, called RapidAIM, to identify potential drugs targeting the gut microbiome. MedBiome uses the platform to 1) develop compounds to stimulate the production of specific microbiome metabolites important to human health and diseases and 2) B2B partnerships for product development. MedBiome has partnerships in place in Europe and China.

Pitch Video

Pitch Deck

Slide Deck

Executive Summary